Skip to main content

Table 4 G-CSF usage at the first course of MVAC chemotherapy

From: Co-administration of dexamethasone increases severity and accelerates onset day of neutropenia in bladder cancer patients on methotrexate, vinblastine, adriamycin and cisplatin chemotherapy: a retrospective cohort study

 

Dex (−) (n = 6)

Dex 1 day (n = 12)

Dex multiday (n = 6)

G-CSF use (%)

50

75

100

P value

 

0.34

0.18

Day of Onset of first G-CSF use

18.0 ± 2.0

15.1 ± 2.7

13.7 ± 1.5

P value

 

0.17

0.04

  1. P values are for G-CSF use with Dex 1 day and multiday versus Dex (−), as determined by Fisher’s exact test
  2. Onset day of G-CSF first use data are mean ± SD. P values are for onset day of G-CSF use with Dex (1 day or multiday) versus Dex (−), as determined by ANOVA with post hoc Tukey’s test
Back to article page

Journal of Pharmaceutical Health Care and Sciences

ISSN: 2055-0294

Contact us